To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer

A Clinical Trial to Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer

The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer.

Participants undergo the following process:

There must be a cancerous lesion available for biopsy or surgery, and enhanced tumor-infiltrating lymphocytes are cultured from ovarian cancer tissue collected from the subject.

These are processed into human cells for administration and injected into the subject.

Administer a fixed dose of CHA-TIL to the subject as a single intravenous infusion and evaluate safety and preliminary efficacy for 6 months.

Inclusion Criteria:

• Recurrent ovarian cancer
• There is a cancerous lesion that can be removed by biopsy or surgery.

Exclusion Criteria:

• Patient with immunodeficiency or autoimmune diseases that may be exacerbated by immunotherapy
• Patient deemed unsuitable by the principal investigator